Philip Morris Lowers Guidance on Zyn Approval Issues

Philip Morris International (PM) has revised its 2024 financial expectations downward due to regulatory hurdles in the approval process for its popular nicotine pouch, Zyn. The company stated that Zyn's sales in the US will grow more slowly than anticipated, negatively impacting overall revenue and profit margins. Philip Morris noted delays in applications for Zyn's approval by the US Food and Drug Administration (FDA). These delays have prevented the company from achieving the growth rate previously forecast. Zyn is a key component of Philip Morris's smoke-free product portfolio, and the company had expected its sales to increase by 30-40% in 2024. Under the new expectations, the company lowered its 2024 earnings per share (EPS) forecast from a range of $5.80-$6.00 to $5.50-$5.70. Additionally, the net revenue growth forecast was revised from 8-10% to 6-8%. These revisions are attributed to uncertainties in Zyn's approval process, as well as foreign exchange fluctuations and increased competitive pressure. Analysts note that Philip Morris's reliance on Zyn poses a risk to the company. Delays in Zyn's approval process could negatively impact the company's smoke-free product strategy. However, the stability of Philip Morris's traditional cigarette sales and growth potential in other markets may partially offset this negative impact. This is not investment advice.